BRPI1012831A2 - forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2. - Google Patents

forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2.

Info

Publication number
BRPI1012831A2
BRPI1012831A2 BRPI1012831A BRPI1012831A BRPI1012831A2 BR PI1012831 A2 BRPI1012831 A2 BR PI1012831A2 BR PI1012831 A BRPI1012831 A BR PI1012831A BR PI1012831 A BRPI1012831 A BR PI1012831A BR PI1012831 A2 BRPI1012831 A2 BR PI1012831A2
Authority
BR
Brazil
Prior art keywords
bcl
dosage form
oral administration
pharmaceutical dosage
family inhibitor
Prior art date
Application number
BRPI1012831A
Other languages
English (en)
Inventor
Liepold Bernd
Packhaeuser Claudia
Kostelac Drazen
Knobloch Martin
Steiger Norbert
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012831(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Priority to BR122018076978-5A priority Critical patent/BR122018076978B1/pt
Publication of BRPI1012831A2 publication Critical patent/BRPI1012831A2/pt
Publication of BRPI1012831B1 publication Critical patent/BRPI1012831B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1012831-0A 2009-06-08 2010-06-08 Forma de dosagem farmacêutica compreendendo uma dispersão sólida de abt-263, processo para preparação da dita forma de dosagem e uso da mesma para o tratamento de distúrbios proliferativos BRPI1012831B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018076978-5A BR122018076978B1 (pt) 2009-06-08 2010-06-08 Forma de dosagem farmacêutica compreendendo uma dispersão sólida de abt-263 contendo solubilizantes, processo para preparação da dita forma de dosagem e uso no tratamento de distúrbios proliferativos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18513009P 2009-06-08 2009-06-08
US61/185,130 2009-06-08
PCT/IB2010/001659 WO2010143074A2 (en) 2009-06-08 2010-06-08 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

Publications (2)

Publication Number Publication Date
BRPI1012831A2 true BRPI1012831A2 (pt) 2018-03-06
BRPI1012831B1 BRPI1012831B1 (pt) 2021-05-18

Family

ID=43063251

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018076978-5A BR122018076978B1 (pt) 2009-06-08 2010-06-08 Forma de dosagem farmacêutica compreendendo uma dispersão sólida de abt-263 contendo solubilizantes, processo para preparação da dita forma de dosagem e uso no tratamento de distúrbios proliferativos
BRPI1012831-0A BRPI1012831B1 (pt) 2009-06-08 2010-06-08 Forma de dosagem farmacêutica compreendendo uma dispersão sólida de abt-263, processo para preparação da dita forma de dosagem e uso da mesma para o tratamento de distúrbios proliferativos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018076978-5A BR122018076978B1 (pt) 2009-06-08 2010-06-08 Forma de dosagem farmacêutica compreendendo uma dispersão sólida de abt-263 contendo solubilizantes, processo para preparação da dita forma de dosagem e uso no tratamento de distúrbios proliferativos

Country Status (38)

Country Link
US (6) US9642796B2 (pt)
EP (3) EP2982366B1 (pt)
JP (2) JP5872459B2 (pt)
KR (2) KR101791404B1 (pt)
CN (2) CN106074391A (pt)
AR (2) AR077021A1 (pt)
AU (1) AU2010258367B2 (pt)
BR (2) BR122018076978B1 (pt)
CA (1) CA2763441C (pt)
CL (1) CL2011003054A1 (pt)
CO (1) CO6480964A2 (pt)
CR (1) CR20170037A (pt)
CY (1) CY1119663T1 (pt)
DK (2) DK2440177T3 (pt)
DO (2) DOP2011000375A (pt)
EC (1) ECSP12011580A (pt)
ES (2) ES2651307T3 (pt)
HK (2) HK1169613A1 (pt)
HR (2) HRP20151342T1 (pt)
HU (2) HUE025638T2 (pt)
IL (2) IL216494A (pt)
LT (1) LT2982366T (pt)
MX (1) MX2011013164A (pt)
MY (1) MY159824A (pt)
NO (1) NO2982366T3 (pt)
NZ (1) NZ597241A (pt)
PE (2) PE20121084A1 (pt)
PL (2) PL2982366T3 (pt)
PT (2) PT2440177E (pt)
RU (2) RU2568599C2 (pt)
SG (1) SG176264A1 (pt)
SI (2) SI2440177T1 (pt)
SM (1) SMT201500317B (pt)
TW (2) TWI540132B (pt)
UA (1) UA104471C2 (pt)
UY (1) UY32695A (pt)
WO (1) WO2010143074A2 (pt)
ZA (1) ZA201108853B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
SG186248A1 (en) 2010-06-09 2013-01-30 Abbvie Inc Solid dispersions containing kinase inhibitors
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
LT2642999T (lt) 2010-11-23 2017-01-25 Abbvie Ireland Unlimited Company Gydymo būdai, naudojant selektyviuosius bcl-2 inhibitorius
PL2643322T3 (pl) 2010-11-23 2018-02-28 Abbvie Inc. Sole i postaci krystaliczne środka indukującego apoptozę
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20160022708A1 (en) * 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
WO2015051252A1 (en) * 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
CA2940451A1 (en) * 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN110960500B (zh) 2014-06-18 2022-10-14 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
WO2017148837A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US11872237B2 (en) * 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
KR20220158725A (ko) * 2020-02-24 2022-12-01 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체
KR20230132496A (ko) * 2021-01-08 2023-09-15 사이로스 파마수티컬스, 인크. 고정 용량의 타미바로텐을 사용하는 치료 용법
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
WO2023172958A1 (en) * 2022-03-08 2023-09-14 Onkosxcel Therapeutics, Llc Stable formulations of talabostat

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
GB9309509D0 (en) * 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
EA200300652A1 (ru) * 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Эфирные производные, полезные в качестве ингибиторов изозимов pde4
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
EP1471887B1 (en) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
EP1480679B1 (en) * 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
JO2479B1 (en) * 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7318503B2 (en) * 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
MX2007014049A (es) * 2005-05-12 2008-02-11 Abbott Lab Activadores de apoptosis.
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
SI1933809T1 (sl) 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
US7151188B1 (en) * 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
EP2037912A2 (en) * 2006-05-15 2009-03-25 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP5277168B2 (ja) * 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP2620157A3 (en) * 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
WO2009073835A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
CA2764187A1 (en) * 2009-06-18 2010-12-23 Abbott Laboratories Stable nanoparticulate drug suspension
US8362014B2 (en) 2009-09-20 2013-01-29 Abbvie Inc. ABT-263 crystalline forms
BR112012014499A2 (pt) 2009-12-22 2016-08-16 Abbott Lab cápsula de abt-263
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
AU2012318242A1 (en) 2011-11-11 2013-05-30 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus

Also Published As

Publication number Publication date
JP2016121159A (ja) 2016-07-07
AU2010258367A1 (en) 2012-01-19
MY159824A (en) 2017-02-15
IL216494A0 (en) 2012-01-31
DK2982366T3 (en) 2018-01-02
NZ597241A (en) 2014-01-31
DK2440177T3 (en) 2015-12-21
RU2011154143A (ru) 2013-07-20
ECSP12011580A (es) 2012-02-29
RU2015141869A3 (pt) 2019-04-19
EP3272334A1 (en) 2018-01-24
PT2440177E (pt) 2015-12-01
TWI471321B (zh) 2015-02-01
UA104471C2 (uk) 2014-02-10
WO2010143074A3 (en) 2011-02-17
PE20121084A1 (es) 2012-09-13
PL2982366T3 (pl) 2018-06-29
HRP20171902T1 (hr) 2018-01-26
SG176264A1 (en) 2012-01-30
BRPI1012831B1 (pt) 2021-05-18
CL2011003054A1 (es) 2012-07-20
CA2763441C (en) 2018-01-02
IL238477A0 (en) 2015-06-30
US20220110951A1 (en) 2022-04-14
RU2015141869A (ru) 2018-12-29
PE20160043A1 (es) 2016-02-11
SI2440177T1 (sl) 2016-01-29
US20170189426A1 (en) 2017-07-06
LT2982366T (lt) 2017-11-27
HUE025638T2 (en) 2016-04-28
UY32695A (es) 2010-12-31
ZA201108853B (en) 2012-08-29
SMT201500317B (it) 2016-02-25
WO2010143074A2 (en) 2010-12-16
US20190269704A1 (en) 2019-09-05
JP6129999B2 (ja) 2017-05-17
BR122018076978B1 (pt) 2021-08-31
PT2982366T (pt) 2017-12-21
RU2568599C2 (ru) 2015-11-20
DOP2011000375A (es) 2011-12-31
US20100310648A1 (en) 2010-12-09
AR077021A1 (es) 2011-07-27
KR101791404B1 (ko) 2017-10-30
HK1169613A1 (en) 2013-02-01
EP2440177A2 (en) 2012-04-18
TW201529572A (zh) 2015-08-01
KR20120027049A (ko) 2012-03-20
HK1220902A1 (zh) 2017-05-19
CO6480964A2 (es) 2012-07-16
RU2711359C2 (ru) 2020-01-16
JP5872459B2 (ja) 2016-03-01
CR20170037A (es) 2017-04-17
AR109816A2 (es) 2019-01-23
CN102802606A (zh) 2012-11-28
KR20170073714A (ko) 2017-06-28
TW201103925A (en) 2011-02-01
KR101751216B1 (ko) 2017-06-28
US9642796B2 (en) 2017-05-09
ES2551860T3 (es) 2015-11-24
PL2440177T3 (pl) 2016-03-31
EP2982366A1 (en) 2016-02-10
HRP20151342T1 (hr) 2016-01-01
ES2651307T3 (es) 2018-01-25
US20210093649A1 (en) 2021-04-01
CN106074391A (zh) 2016-11-09
NO2982366T3 (pt) 2018-02-10
US20240197757A1 (en) 2024-06-20
CY1119663T1 (el) 2018-04-04
DOP2017000057A (es) 2017-04-16
SI2982366T1 (en) 2018-01-31
TWI540132B (zh) 2016-07-01
MX2011013164A (es) 2012-04-20
EP3272334B1 (en) 2019-03-06
AU2010258367B2 (en) 2014-05-01
EP2982366B1 (en) 2017-09-13
JP2012529490A (ja) 2012-11-22
EP2440177B1 (en) 2015-09-16
HUE035727T2 (en) 2018-05-28
CA2763441A1 (en) 2010-12-16
IL216494A (en) 2016-03-31
IL238477A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
BRPI1012831A2 (pt) forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2.
BRPI0906467A2 (pt) forma de dose farmacêutica
IL206159A0 (en) Oral pharmaceutical dosage forms
EP2429506A4 (en) DOSAGE FOR COATED PHARMACEUTICAL CAPSULES
DK2343071T3 (da) Farmaceutiske doseringsformer
BRPI0913434A2 (pt) forma de dosagem farmacêutica em cápsula compreendendo uma formulação de um derivado de indolinona em supensão
BRPI1007484A2 (pt) composição farmacêutica para administração oral
DK2464342T3 (da) Farmaceutisk formulering mod stofmisbrug
BRPI1011681A2 (pt) mecanismo de dosagem para um dispositivo de administração de fármaco
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
DK2482881T3 (da) Mekanisme til indretning til indlevering af lægemiddel
BRPI1011453A2 (pt) formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BR112013014940A2 (pt) composições farmacêuticas de inibidores de fator xa seletivos para administração oral
BRPI0919194A2 (pt) preparação sólida para administração oral
PL2253326T3 (pl) Kompozycja farmaceutyczna do podawania przeznosowego
DK2714042T3 (da) En analgetisk farmaceutisk sammensætning til oral administration
BRPI0919475A2 (pt) composição farmacêutica para administração oral
EP2520300A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HU0900482D0 (en) Pharmaceutical formulation for oral administration
BR112014009547A8 (pt) composição farmacêutica para administração oral, e, sistema de liberação para a administração oral de uma composição farmacêutica bifásica
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: ABBVIE DEUTSCHLAND GMBH AND CO. KG (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF